Souhaitez-vous accéder aux communiqués récents ?

Austin, TX, USA, June 18, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Fluorescent In Situ Hybridization Probe Market Size, Trends and Insights By...

The clinical studies on orelabrutinib covered multiple hematological malignancies, further supporting the excellent efficacy and safety of orelabrutinib.

CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient...

Five in-person poster presentations and two virtual posters highlight Parexel’s thought leadership in real-world evidence, comparative outcomes and regulatory insights across hematologic diseases “At...

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will...

Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 T-cellsCorrelation established between EO2463-induced and B cell...

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only...

- European Commercialization will be Led by X4 Pharmaceuticals’ Partner, Norgine -  - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON, April ...

Veld Pharmaceuticals, announced a collaboration with Chiesi Farmaceutici S.p.A in Africa for Rare Disease Therapies

Austin, TX, USA, March 10, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Intravenous Infusion Pump Market Size, Trends and Insights By Product Type...